Actinium Pharmaceuticals

Actinium Pharmaceuticals ATNM Stock

$1.16   -14.074078%
Add to favorites
Market Cap
$36.47M
LOW - HIGH [24H]
$1.12 - $1.34
VOLUME [24H]
$169.37K
P/E Ratio
3.41
Earnings per share
$0.34
ISIN
US00507W2061
Price   Prediction

Actinium Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Actinium Pharmaceuticals (ATNM) stock price today is 1.16 USD on NYSE American (-14.07% on the day). Updated .

Actinium Pharmaceuticals ATNM Financial and Trading Overview

Actinium Pharmaceuticals stock price 1.16 USD
Previous Close 1.64 USD
Open 1.64 USD
Bid 0 USD x 30000
Ask 0 USD x 360000
Day's Range 1.47 - 1.68 USD
52 Week Range 0.74 - 1.72 USD
Volume 342.32K USD
Avg. Volume 183.34K USD
Market Cap 46.85M USD
Beta (5Y Monthly) 0.261
PE Ratio (TTM) 4.138889
EPS (TTM) 0.34 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 4 USD

ATNM Valuation Measures

Enterprise Value 11.72M USD
Trailing P/E 4.138889
Forward P/E -2.8380954
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1.3350738
Price/Book (mrq) 1.5456432
Enterprise Value/Revenue 0.334
Enterprise Value/EBITDA 1.197

Trading Information

Actinium Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.261
52-Week Change 13.10%
S&P500 52-Week Change 13.32%
52 Week High 1.72 USD
52 Week Low 0.74 USD
50-Day Moving Average 1.28 USD
200-Day Moving Average 1.13 USD

ATNM Share Statistics

Avg. Volume (3 month) 183.34K USD
Avg. Daily Volume (10-Days) 187.49K USD
Shares Outstanding 31.44M
Float 31.26M
Short Ratio 2.52
% Held by Insiders 1.93%
% Held by Institutions 16.80%
Shares Short 593.22K
Short % of Float 1.89%
Short % of Shares Outstanding 1.89%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:30

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 32.22%
Operating Margin (ttm) 27.23%
Gross Margin 100.00%
EBITDA Margin 27.90%

Management Effectiveness

Return on Assets (ttm) 11.57%
Return on Equity (ttm) 45.85%

Income Statement

Revenue (ttm) 35.09M USD
Revenue Per Share (ttm) 1.12 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 35.09M USD
EBITDA 9.79M USD
Net Income Avi to Common (ttm) 11.31M USD
Diluted EPS (ttm) 0.36
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 36.47M USD
Total Cash Per Share (mrq) 1.16 USD
Total Debt (mrq) 1.34M USD
Total Debt/Equity (mrq) 4.43 USD
Current Ratio (mrq) 4.076
Book Value Per Share (mrq) 0.964

Cash Flow Statement

Operating Cash Flow (ttm) -22663000 USD
Levered Free Cash Flow (ttm) 7.14M USD

Profile of Actinium Pharmaceuticals

Country United States
State NY
City New York
Address 100 Park Avenue
ZIP 10017
Phone 646 677 3870
Website https://www.actiniumpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 27

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Q&A For Actinium Pharmaceuticals Stock

What is a current ATNM stock price?

Actinium Pharmaceuticals ATNM stock price today per share is 1.16 USD.

How to purchase Actinium Pharmaceuticals stock?

You can buy ATNM shares on the NYSE American exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Actinium Pharmaceuticals?

The stock symbol or ticker of Actinium Pharmaceuticals is ATNM.

Which industry does the Actinium Pharmaceuticals company belong to?

The Actinium Pharmaceuticals industry is Biotechnology.

How many shares does Actinium Pharmaceuticals have in circulation?

The max supply of Actinium Pharmaceuticals shares is 31.44M.

What is Actinium Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Actinium Pharmaceuticals PE Ratio is 3.41176460 now.

What was Actinium Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Actinium Pharmaceuticals EPS is 0.34 USD over the trailing 12 months.

Which sector does the Actinium Pharmaceuticals company belong to?

The Actinium Pharmaceuticals sector is Healthcare.

Actinium Pharmaceuticals ATNM included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us NYSE American Composite Index XAX US 7740.13 USD —
-2.42
— — 7701.35 USD — 7887.36 USD — — — —
$2.17T
Total marketcap
$70.27B
Total volume
BTC 58.16%   •   ETH 9.88%
Dominance
Select currency